4565 Nxera Pharma Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4565

TSE Prime

Nxera Pharma Co., Ltd.

928

JPY

-8

(-0.85%)

Mar 13, 3:30 pm JST

5.82

USD

Mar 13, 2:30 am EDT

Result

ー

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	15,569	3,436	1,078	382	4.7	0	Feb 14, 2023	IFRS
Dec, 2023	12,766	-9,526	-10,680	-7,193	-87.2	0	Feb 13, 2024	IFRS
Dec, 2024	28,835	-5,423	-4,662	-4,838	-53.9	0	Feb 14, 2025	IFRS
Dec, 2025	29,615	-8,462	-14,950	-12,530	-138.8	0	Feb 13, 2026	IFRS
Dec, 2026 Guidance	41,300	8,200	ー	ー	－	0	Feb 13, 2026	IFRS
YoY	+39.5%	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 12, 2021	ー	ー	ー	ー	0	IFRS
- - - - Results	Feb 10, 2022	17,712	3,775	433	1,017	0	IFRS
Dec, 2022	Feb 10, 2022	Available in future release
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 13, 2024
Dec, 2024	Feb 13, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025
Results	Feb 13, 2026
Dec, 2026	Feb 13, 2026	41,300	8,200	ー	ー	0	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2002	92	-14.8	Available in future release
Mar, 2003	44	-52.2
Mar, 2004	226	+413.6
Mar, 2005	244	+8.0
Mar, 2006	415	+70.1
Mar, 2007	739	+78.1
Mar, 2008	709	-4.1
Mar, 2009	152	-78.6
Mar, 2010	919	+504.6
Mar, 2011	716	-22.1
Mar, 2012	862	+20.4
Mar, 2013	1,958	+127.1
Mar, 2014	2,069	+5.7
Mar, 2015	3,671	+77.4
Mar, 2016	8,151	+122.0
Mar, 2017	18,901	+131.9
Mar, 2018	6,955	-63.2
Dec, 2018 Changed	2,872	－
Dec, 2019	9,726	+238.6
Dec, 2020	8,842	-9.1
Dec, 2021	17,712	+100.3
Dec, 2022	15,569	-12.1
Dec, 2023	12,766	-18.0
Dec, 2024	28,835	+125.9
Dec, 2025	29,615	+2.7
Dec, 2026 Guidance	41,300	+39.5	8,200	－	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	28,835	-5,423	-19	-7.15	-3.13	0.19	-53.9
Dec, 2025	29,615	-8,462	-29	-19.35	-8.75	0.21	-138.8
Dec, 2026 Guidance	41,300	8,200	19.9	ー	ー	0.31	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	29,615	12,389	12,483	9,311	137.8
Fiscal Year	Dec, 2025	Mar, 2017	Mar, 2017	Mar, 2017	Mar, 2017

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	2,146	-4,168	-3,760	-2,060	-25.1	0	Aug 4, 2023	IFRS
Jan - Jun, 2024	12,720	-3,654	-3,158	-4,703	-52.5	0	Aug 9, 2024	IFRS
Jan - Jun, 2025	15,094	-2,756	-3,722	-3,137	-34.8	0	Aug 8, 2025	IFRS
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 13, 2026	IFRS
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 14, 2023	ー	ー	ー	ー	0	IFRS
- - - - Results	Aug 4, 2023	2,146	-4,168	-3,760	-2,060	0	IFRS
Jun, 2024	Feb 13, 2024	Available in future release
Results	Aug 9, 2024
Jun, 2025	Feb 14, 2025
Results	Aug 8, 2025
Jun, 2026	Feb 13, 2026	ー	ー	ー	ー	0	IFRS

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	-9,526	-69,064	-5,273	-63,791	48,329	49,065	31.21	IFRS
Dec, 2024	-5,423	-12,481	-7,718	-4,763	-6,854	32,268	21.30	IFRS
Dec, 2025	-8,462	2,762	-2,668	5,430	-16,028	20,365	15.11	IFRS

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	12,766	-9,526	-10,680	-7,193	-87.2	0	Feb 13, 2024	IFRS
Dec, 2024	28,835	-5,423	-4,662	-4,838	-53.9	0	Feb 14, 2025	IFRS
Dec, 2025	29,615	-8,462	-14,950	-12,530	-138.8	0	Feb 13, 2026	IFRS
YoY	+2.7%	-56.0%	-220.7%	-159.0%	-157.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	4,611	-3,076	-2,796	-3,281	-36.7	-66.7	May 9, 2024	IFRS
Apr - Jun, 2024	8,109	-578	-362	-1,422	-15.9	-7.1	Aug 9, 2024	IFRS
Jul - Sep, 2024	9,263	808	865	1,200	13.4	8.7	Nov 1, 2024	IFRS
Oct - Dec, 2024	6,852	-2,577	-2,369	-1,335	-14.9	-37.6	Feb 14, 2025	IFRS
Jan - Mar, 2025	6,644	-2,193	-2,156	-760	-8.5	-33.0	May 2, 2025	IFRS
Apr - Jun, 2025	8,450	-563	-1,566	-2,377	-26.4	-6.7	Aug 8, 2025	IFRS
Jul - Sep, 2025	6,754	-3,151	-3,116	-1,672	-18.5	-46.7	Oct 31, 2025	IFRS
Oct - Dec, 2025	7,767	-2,555	-8,112	-7,721	-85.5	-32.9	Feb 13, 2026	IFRS
YoY	+13.4%	+0.9%	-242.4%	-478.4%	-474.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	1,207	+3.9	Available in future release
Apr - Jun, 2021	1,916	+41.5
Jul - Sep, 2021	467	-75.8
Oct - Dec, 2021	14,122	+221.0
Jan - Mar, 2022	1,119	-7.3
Apr - Jun, 2022	1,338	-30.2
Jul - Sep, 2022	6,184	+1,224.2
Oct - Dec, 2022	6,928	-50.9
Jan - Mar, 2023	943	-15.7
Apr - Jun, 2023	1,203	-10.1
Jul - Sep, 2023	3,328	-46.2
Oct - Dec, 2023	7,292	+5.3
Jan - Mar, 2024	4,611	+389.0
Apr - Jun, 2024	8,109	+574.1
Jul - Sep, 2024	9,263	+178.3
Oct - Dec, 2024	6,852	-6.0
Jan - Mar, 2025	6,644	+44.1
Apr - Jun, 2025	8,450	+4.2
Jul - Sep, 2025	6,754	-27.1
Oct - Dec, 2025	7,767	+13.4	-2,555	+0.9	-8,112	-242.4	-85.5	-473.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	15,082	12,955	13,515	11,150	165.3
Fiscal Year	Jun, 2016	Jun, 2016	Jun, 2016	Jun, 2016	Jun, 2016

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2023	746.92	42.5	157,198	66,810	-16,104	1.11	Feb 13, 2024	IFRS
Dec, 2024	762.15	45.2	151,498	68,518	-20,942	0.99	Feb 14, 2025	IFRS
Dec, 2025	674.04	45.3	134,787	60,997	-17,546	0.94	Feb 13, 2026	IFRS

Nxera Pharma Co., Ltd.(4565) Financial Results